CC
ABVX

Centiva Capital’s Abivax ABVX Stock Holding History

Centiva Capital’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$601K Sell
4,512
-52,638
-92% -$5.96M 0.01% 827
2026
Q1 		$6.36M Buy
+57,150
New +$6.76M 0.05% 248

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's ABVX Position: Q2 2026 in Review

Centiva Capital reduced its Abivax (ABVX) stake by 92% in Q2 2026, selling an estimated $5.96M and leaving 4,512 shares worth $601K. The position accounts for 0.01% of the portfolio, ranked #827.

Centiva Capital first reported a position in ABVX in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.36M in Q1 2026. 302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Centiva Capital held 4,512 shares of Abivax worth $601K as of Q2 2026.
  • Centiva Capital sold 52,638 Abivax shares in Q2 2026, an estimated $5.96M.
  • Abivax made up 0.01% of Centiva Capital's portfolio in Q2 2026, its #827 holding.
  • Centiva Capital first reported a position in Abivax in Q1 2026 and has held it in 2 quarters since.
  • Centiva Capital's Abivax position peaked at $6.36M in Q1 2026.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.